Lipoprotein (a) Test

The Lipoprotein (a) [Lp(a)] test measures the level of Lp(a) in the blood. Lp(a) is an LDL-like lipoprotein particle attached to a unique protein called apolipoprotein (a) [apo(a)], making it highly atherogenic and prone to promoting plaque buildup in arterial walls. Unlike most cholesterol markers, Lp(a) levels are largely genetically determined and remain relatively stable throughout life, making Lp(a) an important inherited cardiovascular risk factor that may not be detected through routine lipid profile testing. Elevated Lp(a) levels are associated with an increased risk of atherosclerosis, coronary artery disease, heart attack, stroke, and aortic valve disease, even in individuals with otherwise normal lipid profiles.

Who should get this test done?

This test is recommended for individuals who:

●     Have a personal or family history of premature cardiovascular disease, such as a heart attack or stroke before age 55 in men or 65 in women

●     Have experienced a heart attack, stroke, or coronary artery disease despite normal or well-controlled LDL levels

●     Have borderline cardiovascular risk and require further risk stratification

●     Have a family history of elevated Lp(a), as it is strongly hereditary

●     Are considering preventive cardiovascular therapies and need a comprehensive lipid risk assessment

Why consider this test?

Since Lp(a) is not included in a standard lipid profile, many people with elevated levels remain unaware of their increased cardiovascular risk. This test helps:

●     Uncover hidden cardiovascular risk – Identifies individuals at increased risk of heart attack and stroke despite normal LDL and total cholesterol levels.

●     Assess genetic predisposition – Evaluates inherited cardiovascular risk, as Lp(a) levels are primarily determined by genetics and are not significantly affected by diet or exercise.

●     Explain premature cardiovascular events – Helps investigate early-onset heart disease or stroke in individuals without traditional risk factors.

●     Refine risk stratification – Improves cardiovascular risk assessment in people with borderline risk profiles, supporting more informed treatment decisions.

●     Guide preventive therapy – Encourages more aggressive management of modifiable risk factors such as LDL cholesterol, blood pressure, and lifestyle habits.

More Information

Lp(a) is unique among cardiovascular risk markers because its levels are up to 90% genetically determined and are largely unaffected by diet, exercise, or standard lipid-lowering therapies such as statins. This makes it an independent inherited risk factor that cannot be managed through lifestyle changes alone. Elevated Lp(a) promotes atherosclerosis through two mechanisms: its LDL-like core deposits cholesterol in arterial walls, while its apolipoprotein(a) component impairs clot breakdown, increasing thrombotic risk. Because Lp(a) is not included in a routine lipid profile, many high-risk individuals remain unaware of elevated levels. Targeted Lp(a)-lowering therapies are currently under active clinical investigation and represent a promising area of cardiovascular prevention.

Other names:

●     Lp(a) Test

●     Lipoprotein Little a Test

●     Lp(a) Cholesterol Test

●     Sinking Pre-Beta Lipoprotein Test

●     Apolipoprotein (a) Test